Can a drug combo wake up 'Cold' tumors to immunotherapy?
NCT ID NCT05000294
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times
Summary
This study tests whether combining two drugs (atezolizumab and tivozanib) can help the immune system attack cancers that usually don't respond to immunotherapy, like certain prostate, pancreatic, and breast cancers. About 29 adults with advanced or metastatic disease who have already tried at least one prior treatment will receive the combination. The goal is to see if this approach can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.